
    
      This study was designed to prove safety and efficacy of aripiprazole in the treatment of
      acutely relapsed patients with diagnoses of schizophrenia or schizoaffective disorder in
      Korea and to confirm the maintenance of efficacy and safety during maintenance period and the
      changes in emotional factors and social functions.

      After administering 15 mg/day of aripiprazole for two weeks, the test may change the dose
      within the range of 10 mg and 30 mg per day by clinical judgment. (Medication duration: 8
      weeks (acute phase) + 18 weeks (maintenance phase)] + 26 weeks (extension phase), *total 52
      weeks)
    
  